Inhibitor binding to topoisomerase II leading to infant leukaemia:
This Adverse Outcome Pathway (AOP) describes the linkages between the perturbation of the normal topoisomerase II enzyme function and infant leukaemia. Infant leukaemia is a rare haematological disease (1 in 106 newborns, accounting for 10% of all childhood acute lymphoblastic leukaemias) of develop...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | , , , |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Paris
OECD Publishing
2022
|
| Schriftenreihe: | OECD Series on Adverse Outcome Pathways
no.21 |
| Schlagworte: | |
| Online-Zugang: | UBA01 TUM01 UBG01 UEI01 UER01 UPA01 UBR01 UBW01 FFW01 FNU01 EUV01 FRO01 FHR01 FHN01 FHI01 Volltext |
| Zusammenfassung: | This Adverse Outcome Pathway (AOP) describes the linkages between the perturbation of the normal topoisomerase II enzyme function and infant leukaemia. Infant leukaemia is a rare haematological disease (1 in 106 newborns, accounting for 10% of all childhood acute lymphoblastic leukaemias) of developmental origin, manifesting soon after birth (< 1 year old). The present AOP describes how interference of stressors with DNA topoisomerase II enzyme can possibly result in DNA double-strand break and chromosomal rearrangement during intrauterine development and lead to infant leukaemia, manifesting soon after birth. The proposed AOP is supported by a number of evidences by means of using etoposide as a model compound to empirically support the linkage between the proposed molecular initiating event and the adverse outcome. This AOP also identifies several knowledge gaps, the main ones being the identification of the initiating cell and the investigation of TopoII poisons in a robust model; thus, the present AOP may be modified in future on the basis of new evidence. This AOP is referred to as AOP 202 in the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki) |
| Beschreibung: | 1 Online-Ressource (64 Seiten) |
| DOI: | 10.1787/4782fbfc-en |
Internformat
MARC
| LEADER | 00000nmm a22000001cb4500 | ||
|---|---|---|---|
| 001 | BV048943201 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 230510s2022 |||| o||u| ||||||eng d | ||
| 024 | 7 | |a 10.1787/4782fbfc-en |2 doi | |
| 035 | |a (ZDB-13-SOC)084083786 | ||
| 035 | |a (OCoLC)1379381108 | ||
| 035 | |a (DE-599)KEP084083786 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-521 |a DE-1028 |a DE-573 |a DE-92 |a DE-898 |a DE-1049 |a DE-861 |a DE-91 |a DE-384 |a DE-473 |a DE-355 |a DE-20 |a DE-824 |a DE-29 |a DE-739 |a DE-188 | ||
| 100 | 1 | |a Pelkonen, Olavi |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Inhibitor binding to topoisomerase II leading to infant leukaemia |c Olavi, Pelkonen ... [et al] |
| 264 | 1 | |a Paris |b OECD Publishing |c 2022 | |
| 300 | |a 1 Online-Ressource (64 Seiten) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a OECD Series on Adverse Outcome Pathways |v no.21 | |
| 520 | 3 | |a This Adverse Outcome Pathway (AOP) describes the linkages between the perturbation of the normal topoisomerase II enzyme function and infant leukaemia. Infant leukaemia is a rare haematological disease (1 in 106 newborns, accounting for 10% of all childhood acute lymphoblastic leukaemias) of developmental origin, manifesting soon after birth (< 1 year old). The present AOP describes how interference of stressors with DNA topoisomerase II enzyme can possibly result in DNA double-strand break and chromosomal rearrangement during intrauterine development and lead to infant leukaemia, manifesting soon after birth. The proposed AOP is supported by a number of evidences by means of using etoposide as a model compound to empirically support the linkage between the proposed molecular initiating event and the adverse outcome. This AOP also identifies several knowledge gaps, the main ones being the identification of the initiating cell and the investigation of TopoII poisons in a robust model; thus, the present AOP may be modified in future on the basis of new evidence. This AOP is referred to as AOP 202 in the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki) | |
| 650 | 4 | |a Environment | |
| 700 | 1 | |a Terron, Andrea |4 MitwirkendeR |4 ctb | |
| 700 | 1 | |a Hernandez, Antonio F... |4 MitwirkendeR |4 ctb | |
| 700 | 1 | |a Menendez, Pablo |4 MitwirkendeR |4 ctb | |
| 700 | 1 | |a Hougaard Bennekou, Susanne |4 MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |u https://doi.org/10.1787/4782fbfc-en |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-13-SOC | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-034207048 | ||
| 966 | e | |u https://doi.org/10.1787/4782fbfc-en |l UBA01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/4782fbfc-en |l TUM01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/4782fbfc-en |l UBG01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/4782fbfc-en |l UEI01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/4782fbfc-en |l UER01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/4782fbfc-en |l UPA01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/4782fbfc-en |l UBR01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/4782fbfc-en |l UBW01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/4782fbfc-en |l FFW01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/4782fbfc-en |l FNU01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/4782fbfc-en |l EUV01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/4782fbfc-en |l FRO01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/4782fbfc-en |l FHR01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/4782fbfc-en |l FHN01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
| 966 | e | |u https://doi.org/10.1787/4782fbfc-en |l FHI01 |p ZDB-13-SOC |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804185147190280192 |
|---|---|
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Pelkonen, Olavi |
| author2 | Terron, Andrea Hernandez, Antonio F.. Menendez, Pablo Hougaard Bennekou, Susanne |
| author2_role | ctb ctb ctb ctb |
| author2_variant | a t at a f h af afh p m pm b s h bs bsh |
| author_facet | Pelkonen, Olavi Terron, Andrea Hernandez, Antonio F.. Menendez, Pablo Hougaard Bennekou, Susanne |
| author_role | aut |
| author_sort | Pelkonen, Olavi |
| author_variant | o p op |
| building | Verbundindex |
| bvnumber | BV048943201 |
| collection | ZDB-13-SOC |
| ctrlnum | (ZDB-13-SOC)084083786 (OCoLC)1379381108 (DE-599)KEP084083786 |
| discipline | Wirtschaftswissenschaften |
| discipline_str_mv | Wirtschaftswissenschaften |
| doi_str_mv | 10.1787/4782fbfc-en |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03882nmm a22005531cb4500</leader><controlfield tag="001">BV048943201</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">230510s2022 |||| o||u| ||||||eng d</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/4782fbfc-en</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-13-SOC)084083786</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1379381108</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KEP084083786</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-521</subfield><subfield code="a">DE-1028</subfield><subfield code="a">DE-573</subfield><subfield code="a">DE-92</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-1049</subfield><subfield code="a">DE-861</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-384</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-188</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Pelkonen, Olavi</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Inhibitor binding to topoisomerase II leading to infant leukaemia</subfield><subfield code="c">Olavi, Pelkonen ... [et al]</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (64 Seiten)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">OECD Series on Adverse Outcome Pathways</subfield><subfield code="v">no.21</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">This Adverse Outcome Pathway (AOP) describes the linkages between the perturbation of the normal topoisomerase II enzyme function and infant leukaemia. Infant leukaemia is a rare haematological disease (1 in 106 newborns, accounting for 10% of all childhood acute lymphoblastic leukaemias) of developmental origin, manifesting soon after birth (< 1 year old). The present AOP describes how interference of stressors with DNA topoisomerase II enzyme can possibly result in DNA double-strand break and chromosomal rearrangement during intrauterine development and lead to infant leukaemia, manifesting soon after birth. The proposed AOP is supported by a number of evidences by means of using etoposide as a model compound to empirically support the linkage between the proposed molecular initiating event and the adverse outcome. This AOP also identifies several knowledge gaps, the main ones being the identification of the initiating cell and the investigation of TopoII poisons in a robust model; thus, the present AOP may be modified in future on the basis of new evidence. This AOP is referred to as AOP 202 in the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Environment</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Terron, Andrea</subfield><subfield code="4">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hernandez, Antonio F...</subfield><subfield code="4">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Menendez, Pablo</subfield><subfield code="4">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hougaard Bennekou, Susanne</subfield><subfield code="4">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1787/4782fbfc-en</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-034207048</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/4782fbfc-en</subfield><subfield code="l">UBA01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/4782fbfc-en</subfield><subfield code="l">TUM01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/4782fbfc-en</subfield><subfield code="l">UBG01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/4782fbfc-en</subfield><subfield code="l">UEI01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/4782fbfc-en</subfield><subfield code="l">UER01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/4782fbfc-en</subfield><subfield code="l">UPA01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/4782fbfc-en</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/4782fbfc-en</subfield><subfield code="l">UBW01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/4782fbfc-en</subfield><subfield code="l">FFW01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/4782fbfc-en</subfield><subfield code="l">FNU01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/4782fbfc-en</subfield><subfield code="l">EUV01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/4782fbfc-en</subfield><subfield code="l">FRO01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/4782fbfc-en</subfield><subfield code="l">FHR01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/4782fbfc-en</subfield><subfield code="l">FHN01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1787/4782fbfc-en</subfield><subfield code="l">FHI01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV048943201 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T21:58:30Z |
| indexdate | 2024-07-10T09:50:36Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-034207048 |
| oclc_num | 1379381108 |
| open_access_boolean | |
| owner | DE-521 DE-1028 DE-573 DE-92 DE-898 DE-BY-UBR DE-1049 DE-861 DE-91 DE-BY-TUM DE-384 DE-473 DE-BY-UBG DE-355 DE-BY-UBR DE-20 DE-824 DE-29 DE-739 DE-188 |
| owner_facet | DE-521 DE-1028 DE-573 DE-92 DE-898 DE-BY-UBR DE-1049 DE-861 DE-91 DE-BY-TUM DE-384 DE-473 DE-BY-UBG DE-355 DE-BY-UBR DE-20 DE-824 DE-29 DE-739 DE-188 |
| physical | 1 Online-Ressource (64 Seiten) |
| psigel | ZDB-13-SOC |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | OECD Publishing |
| record_format | marc |
| series2 | OECD Series on Adverse Outcome Pathways |
| spelling | Pelkonen, Olavi Verfasser aut Inhibitor binding to topoisomerase II leading to infant leukaemia Olavi, Pelkonen ... [et al] Paris OECD Publishing 2022 1 Online-Ressource (64 Seiten) txt rdacontent c rdamedia cr rdacarrier OECD Series on Adverse Outcome Pathways no.21 This Adverse Outcome Pathway (AOP) describes the linkages between the perturbation of the normal topoisomerase II enzyme function and infant leukaemia. Infant leukaemia is a rare haematological disease (1 in 106 newborns, accounting for 10% of all childhood acute lymphoblastic leukaemias) of developmental origin, manifesting soon after birth (< 1 year old). The present AOP describes how interference of stressors with DNA topoisomerase II enzyme can possibly result in DNA double-strand break and chromosomal rearrangement during intrauterine development and lead to infant leukaemia, manifesting soon after birth. The proposed AOP is supported by a number of evidences by means of using etoposide as a model compound to empirically support the linkage between the proposed molecular initiating event and the adverse outcome. This AOP also identifies several knowledge gaps, the main ones being the identification of the initiating cell and the investigation of TopoII poisons in a robust model; thus, the present AOP may be modified in future on the basis of new evidence. This AOP is referred to as AOP 202 in the Collaborative Adverse Outcome Pathway Wiki (AOP-Wiki) Environment Terron, Andrea MitwirkendeR ctb Hernandez, Antonio F... MitwirkendeR ctb Menendez, Pablo MitwirkendeR ctb Hougaard Bennekou, Susanne MitwirkendeR ctb https://doi.org/10.1787/4782fbfc-en Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Pelkonen, Olavi Inhibitor binding to topoisomerase II leading to infant leukaemia Environment |
| title | Inhibitor binding to topoisomerase II leading to infant leukaemia |
| title_auth | Inhibitor binding to topoisomerase II leading to infant leukaemia |
| title_exact_search | Inhibitor binding to topoisomerase II leading to infant leukaemia |
| title_exact_search_txtP | Inhibitor binding to topoisomerase II leading to infant leukaemia |
| title_full | Inhibitor binding to topoisomerase II leading to infant leukaemia Olavi, Pelkonen ... [et al] |
| title_fullStr | Inhibitor binding to topoisomerase II leading to infant leukaemia Olavi, Pelkonen ... [et al] |
| title_full_unstemmed | Inhibitor binding to topoisomerase II leading to infant leukaemia Olavi, Pelkonen ... [et al] |
| title_short | Inhibitor binding to topoisomerase II leading to infant leukaemia |
| title_sort | inhibitor binding to topoisomerase ii leading to infant leukaemia |
| topic | Environment |
| topic_facet | Environment |
| url | https://doi.org/10.1787/4782fbfc-en |
| work_keys_str_mv | AT pelkonenolavi inhibitorbindingtotopoisomeraseiileadingtoinfantleukaemia AT terronandrea inhibitorbindingtotopoisomeraseiileadingtoinfantleukaemia AT hernandezantoniof inhibitorbindingtotopoisomeraseiileadingtoinfantleukaemia AT menendezpablo inhibitorbindingtotopoisomeraseiileadingtoinfantleukaemia AT hougaardbennekoususanne inhibitorbindingtotopoisomeraseiileadingtoinfantleukaemia |